News

Dermira, Inc. announced that detailed primary results of its Phase 2b study of lebrikizumab in patients with moderate-to-severe atopic dermatitis will be reported at the 39th Annual…
Read More...

Alexion Pharmaceuticals and Stealth BioTherapeutics Corp announced an agreement for an option to co-develop and commercialize elamipretide for mitochondrial diseases. Currently being…
Read More...

Avacta Group plc announces that it has entered a collaboration and option agreement with ADC Therapeutics SA (Lausanne, CH), a clinical-stage oncology-focused biotechnology company…
Read More...

Clinigen Group plc has launched a Managed Access Program for Progenics Pharmaceuticals, Inc., an oncology company developing innovative targeted medicines and artificial intelligence to…
Read More...

Neumentum Inc., a pharmaceutical company dedicated to transforming the way pain is treated, announced it has entered into a global licensing agreement with Janssen Pharmaceutica NV and…
Read More...

VirTrial has been awarded an FDA-approved hybrid decentralized clinical trial (DCT) with Hope Biosciences. The study provides Hope Biosciences’ autologous, adipose-derived…
Read More...

Advaxis, Inc. announced a research collaboration agreement with the University of California Los Angeles (UCLA) to conduct preclinical studies evaluating the Company’s Lm technology in…
Read More...

CURE Pharmaceutical, an innovative drug delivery and development company, announces the expansion of its oral drug delivery product line creating CUREform which includes CUREfilm, one…
Read More...

Adaptimmune Therapeutics plc and Cryoport, Inc. announce a 3-year agreement to ensure safe and fully monitored transport of Adaptimmune’s cell therapies. Optimizing manufacturing and…
Read More...

Ionis Pharmaceuticals, Inc. announced that the company has been notified by its partner Bayer about the decision to advance IONIS-FXI-LRx following positive clinical results.…
Read More...

bluebird bio, Inc. and Novo Nordisk A/S (NVO) announced that they have entered into a research collaboration to jointly develop next-generation in vivo genome editing treatments for…
Read More...

Viela Bio, Inc. and Mitsubishi Tanabe Pharma Corporation announced a collaboration focused on the development and commercialization of inebilizumab – Viela’s humanized anti-CD19…
Read More...

Alcami Corporation announced the launch of its new rapid sterility offering, a service that leverages cutting-edge microbiological testing technology to deliver significantly faster…
Read More...

Hoth Therapeutics, Inc. a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis–also known as eczema–as…
Read More...

IDEAYA Biosciences, Inc., an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics to treat cancer, announces it has dosed its…
Read More...

Novartis announced that the U.S. Food and Drug Administration (FDA) approved Beovu (brolucizumab) injection, also known as RTH258 for the treatment of wet age-related macular…
Read More...

GlaxoSmithKline plc announced a five-year collaboration with Lyell Immunopharma, a San Francisco biotechnology company, to develop new technologies to improve cell therapies for cancer…
Read More...

Pfenex Inc. announced that the U.S. Food and Drug Administration (FDA) has approved the new drug application for PF708 submitted under the 505(b)(2) regulatory pathway, with Forteo…
Read More...

Akcea Therapeutics, and Pfizer announced that the companies have entered into a worldwide exclusive licensing agreement for AKCEA-ANGPTL3-LRx, an investigational antisense therapy being…
Read More...

AstraZeneca announced that the US Food and Drug Administration (FDA) has approved the self-administration of Fasenra (benralizumab) in a pre-filled, single-use auto-injector (the…
Read More...